Companies › Opus Genetics
4 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 3; Ophthalmology, Metabolic and endocrine; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Phentolamine Ophthalmic Solution 0.75% Non-selective alpha-1 and alpha-2 adrenergic antagonist | ADRA1A, ADRA1B, ADRA1D, ADRA2A | Phase 3 | Vision Loss Night; Insulin Resistance | Aug 2027 |
| OPGx-001 AAV8 vector expressing human LCA5 gene | LCA5 | Phase 1 | LCA5 | Jun 2028 |
| OPGx-BEST1 Gene therapy delivering BEST1 gene via subretinal injection | BEST1 | Phase 1 | ARB | Aug 2030 |
| OPGx-RDH12 Gene therapy delivering functional RDH12 gene to retinal cells | RDH12 | Phase 1 | Leber Congenital Amaurosis | Dec 2032 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03318094 | Phentolamine Ophthalmic Solution 0.75% | Phase 1 | Insulin Resistance | Metabolic and endocrine | Nov 2026 |
| NCT07140783 | Phentolamine Ophthalmic Solution 0.75% | Phase 3 | Vision Loss Night | Ophthalmology | Aug 2027 |
| NCT05616793 | OPGx-001 | Phase 1 | LCA5 | Ophthalmology | Jun 2028 |
| NCT07185256 | OPGx-BEST1 | Phase 1 | ARB | Ophthalmology | Aug 2030 |
| NCT07681778 | OPGx-RDH12 | Phase 1 | Leber Congenital Amaurosis | Ophthalmology | Dec 2032 |
Cash of $89m on 2026-06-30; operating cash outflow about $50m a year; runway about 21 months at that burn, to Apr 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Santen SAS Berlin-Chemie AG Menarini Group Applied Biology ARS Pharmaceuticals
ProQR Therapeutics Ocugen Kiora Pharmaceuticals Laboratoires Thea Alcon Research
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.